Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585162 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4EADRB3ADRB1 | |
| SCHEMBL4583955 | 0.87 | KMT2A (0.54) | MEN1KMT2AKDM4E | |
| SCHEMBL4583951 | 0.87 | KMT2A (0.54) | MEN1KMT2AKDM4E | |
| SCHEMBL4585446 | 0.86 | MEN1 (0.57) | MEN1KMT2AKDM4ECYP1A2CYP2C19 | |
| SCHEMBL4585449 | 0.86 | MEN1 (0.57) | MEN1KMT2AKDM4ECYP1A2CYP2C19 | |
| SCHEMBL5703835 | 0.86 | MEN1 (0.45) | MEN1KMT2AKDM4EADRB3ADRB1 | |
| SCHEMBL6805613 | 0.83 | ADRB3 (0.45) | ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL6805619 | 0.83 | ADRB3 (0.45) | ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL4396503 | 0.80 | ADRB1 (0.45) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4396505 | 0.80 | ADRB1 (0.45) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | MEN1 4146/4885KMT2A 630/4885KDM4E 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.